FURIN

13,232 patent compounds predicted against FURIN, 5,212 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Semapimod (SCHEMBL435405)	0.85	14/20
Semapimod (SCHEMBL1649211)	0.81	14/20
SCHEMBL4807610	0.51	9/20
Hydrochloric Acid (SCHEMBL1886710)	0.73	8/20
Hydrochloric Acid (SCHEMBL1886711)	0.73	8/20
SCHEMBL2954348	0.44	7/20
Hydrochloric Acid (SCHEMBL2274914)	0.43	7/20
SCHEMBL2191312	0.43	7/20
SCHEMBL2191316	0.43	7/20
SCHEMBL5442050	0.56	6/20
SCHEMBL2508780	0.42	6/20
Lauroguadine (SCHEMBL1651264)	0.78	5/20
Hydrochloric Acid (SCHEMBL1885706)	0.60	5/20
Hydrochloric Acid (SCHEMBL1885709)	0.60	5/20
Hydrochloric Acid (SCHEMBL1885713)	0.60	5/20
SCHEMBL1269633	0.44	5/20
SCHEMBL1527410	0.42	5/20
SCHEMBL1527412	0.42	5/20
SCHEMBL4914693	0.55	4/20
Trifluoroacetic Acid (SCHEMBL3500386)	0.50	4/20

Clinical trials — most relevant to FURIN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Telmisartan for Treatment of COVID-19 Patients	PHASE4	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19	PHASE2/PHASE3	UNKNOWN
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients	PHASE2	WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	PHASE2	COMPLETED
DEFINE - Evaluating Therapies for COVID-19	PHASE1/PHASE2	COMPLETED
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.	PHASE1/PHASE2	UNKNOWN
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	PHASE2	COMPLETED
Nebulised BromAc in Healthy Volunteers	PHASE1	COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)	PHASE1	COMPLETED
Association Between Periodontitis and Coronavirus Disease (COVID-19)	nan	COMPLETED
Periodontal Health in Post COVID-19 Patients	nan	UNKNOWN
Cardiac Injury in COVID-19: a Pathology Study	nan	UNKNOWN
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients	nan	UNKNOWN
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort	nan	UNKNOWN
Impact of the Genetic Polymorphism on COVID-19 in Egypt	nan	UNKNOWN
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.	nan	UNKNOWN
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).	nan	COMPLETED
COVID-19 on Placental Gene Expression and Pathology	nan	COMPLETED
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study	nan	WITHDRAWN
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids	nan	WITHDRAWN
Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.	nan	UNKNOWN
Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination	nan	COMPLETED
The Effect of RAAS Blockers on ACE2 Levels	nan	COMPLETED
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID	nan	RECRUITING
Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults	nan	COMPLETED
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX)	nan	COMPLETED
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FURIN binder may also engage these)

Protein	Name	Similarity
Q28193	—	1.000	Q28193 →
P23377	—	1.000	P23377 →
P23188	—	1.000	P23188 →
Q63415	—	0.996	Q63415 →
P29119	—	0.995	P29119 →
P28841	—	0.994	P28841 →
Q9GLR0	—	0.993	Q9GLR0 →
P21661	—	0.992	P21661 →
PCSK6	Proprotein convertase subtilisin/kexin type 6	0.991	landscape →
P16519	—	0.991	P16519 →
Q9VBC7	—	0.990	Q9VBC7 →
Q03333	—	0.988	Q03333 →
P29121	—	0.988	P29121 →
Q5REC2	—	0.987	Q5REC2 →
G5ECN9	—	0.987	G5ECN9 →
Q04592	—	0.987	Q04592 →
Q6UW60	—	0.987	Q6UW60 →
Q92824	—	0.987	Q92824 →
LOXL3	Lysyl oxidase homolog 3	0.986	landscape →
Q78EH2	—	0.986	Q78EH2 →
Q3U435	—	0.985	Q3U435 →
Q9NJ15	—	0.985	Q9NJ15 →
P41413	—	0.985	P41413 →
Q9Z175	—	0.984	Q9Z175 →
P53690	—	0.984	P53690 →
O88917	—	0.984	O88917 →
Q95220	—	0.984	Q95220 →
Q96SM3	—	0.983	Q96SM3 →
Q10739	—	0.983	Q10739 →
P63240	—	0.983	P63240 →